NovoCure’s (NVCR) Neutral Rating Reiterated at Wedbush

Wedbush restated their neutral rating on shares of NovoCure (NASDAQ:NVCR) in a report released on Thursday,Benzinga reports. Wedbush currently has a $18.00 price target on the medical equipment provider’s stock.

Other equities research analysts have also issued reports about the company. JPMorgan Chase & Co. dropped their price target on NovoCure from $25.00 to $23.00 and set a “neutral” rating on the stock in a research report on Monday, October 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a report on Wednesday, October 8th. HC Wainwright reduced their price target on shares of NovoCure from $42.00 to $39.00 and set a “buy” rating on the stock in a research report on Tuesday, January 13th. Finally, Evercore ISI set a $20.00 price objective on shares of NovoCure in a research report on Monday, January 5th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, NovoCure currently has a consensus rating of “Hold” and a consensus target price of $25.50.

NovoCure Stock Performance

Shares of NovoCure stock opened at $13.64 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.50 and a current ratio of 1.55. NovoCure has a 1 year low of $10.70 and a 1 year high of $27.47. The firm’s 50-day simple moving average is $12.77 and its 200-day simple moving average is $13.16. The firm has a market cap of $1.53 billion, a PE ratio of -8.47 and a beta of 0.73.

NovoCure (NASDAQ:NVCR) last announced its quarterly earnings data on Thursday, October 30th. The medical equipment provider reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.09. NovoCure had a negative return on equity of 50.29% and a negative net margin of 27.66%.The firm had revenue of $167.20 million during the quarter, compared to analyst estimates of $158.81 million. During the same period in the previous year, the company earned ($0.28) earnings per share. NovoCure’s quarterly revenue was up 7.8% on a year-over-year basis. Equities analysts forecast that NovoCure will post -1.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. SJS Investment Consulting Inc. acquired a new stake in shares of NovoCure in the third quarter valued at approximately $41,000. Larson Financial Group LLC increased its position in NovoCure by 662.1% in the 3rd quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock valued at $53,000 after acquiring an additional 3,562 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in NovoCure by 17.1% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,307 shares of the medical equipment provider’s stock valued at $77,000 after acquiring an additional 629 shares in the last quarter. Headlands Technologies LLC bought a new stake in NovoCure during the 2nd quarter valued at $88,000. Finally, Acadian Asset Management LLC acquired a new position in NovoCure during the 1st quarter worth $87,000. 84.61% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Piper Sandler reaffirmed its Buy rating on NovoCure, supporting demand from growth-oriented investors who focus on long‑term upside potential. Piper Sandler Remains a Buy on NovoCure (NVCR)
• Neutral Sentiment: Wells Fargo moved to a Hold on NVCR, which is neither bullish nor bearish but reduces conviction among buyers waiting for stronger fundamental signals. NovoCure (NVCR) Gets a Hold from Wells Fargo
• Neutral Sentiment: Wedbush reaffirmed a neutral rating with an $18 price target (implying meaningful upside from current levels), a signal that some brokerages see potential but want better near‑term evidence of margin or revenue acceleration. Benzinga
• Neutral Sentiment: Market consensus across analysts remains a “Hold,” reflecting mixed views and likely contributing to muted trading volume and hesitation among broader investor groups. NovoCure Given Consensus Rating of “Hold”
• Negative Sentiment: HC Wainwright cut multiple near‑term and multi‑year EPS forecasts (Q1–Q4 2026, FY2026–2028 and FY2029) and trimmed its price view — even while maintaining a Buy and a $39 target — signaling weaker expected profitability and introducing downside risk to sentiment. That cluster of estimate cuts is the most direct negative catalyst driving selling pressure. HC Wainwright Lowers NovoCure (NVCR) Price Target to $39.00

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.